Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents : data from the ENEIDA registry
© The Author(s), 2024..
Background: Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC) but little is known when it is used as the second anti-TNF.
Objectives: To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients.
Design: Retrospective observational study.
Methods: Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naïve to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially).
Results: Overall, 473 UC patients were included (330 IVi and 143 SCi). Clinical response at week 14 was 42.7% and 48.3% in the IVi and SCi groups (non-statistically significant), respectively. Clinical remission rates at week 52 were 32.8% and 31.4% in the IVi and SCi groups (nonsignificant differences), respectively. A propensity-matched score analysis showed a higher clinical response rate at week 14 in the SCi group and higher treatment persistence in the IVi group. Regarding long-term outcomes, dose escalation and discontinuation due to the primary failure of the first anti-TNF and more severe disease activity at the beginning of the second anti-TNF were inversely associated with clinical remission.
Conclusion: The use of a second anti-TNF for UC seems to be reasonable in terms of efficacy, although it is particularly reduced in the case of the primary failure of the first anti-TNF. Whether the second anti-TNF is infliximab or subcutaneous does not seem to affect efficacy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Therapeutic advances in gastroenterology - 17(2024) vom: 16., Seite 17562848231221713 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Adalimumab |
|---|
| Anmerkungen: |
Date Revised 09.01.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/17562848231221713 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366785478 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366785478 | ||
| 003 | DE-627 | ||
| 005 | 20240114233149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/17562848231221713 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1253.xml |
| 035 | |a (DE-627)NLM366785478 | ||
| 035 | |a (NLM)38187926 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Calafat, Margalida |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents |b data from the ENEIDA registry |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.01.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s), 2024. | ||
| 520 | |a Background: Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC) but little is known when it is used as the second anti-TNF | ||
| 520 | |a Objectives: To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients | ||
| 520 | |a Design: Retrospective observational study | ||
| 520 | |a Methods: Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naïve to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially) | ||
| 520 | |a Results: Overall, 473 UC patients were included (330 IVi and 143 SCi). Clinical response at week 14 was 42.7% and 48.3% in the IVi and SCi groups (non-statistically significant), respectively. Clinical remission rates at week 52 were 32.8% and 31.4% in the IVi and SCi groups (nonsignificant differences), respectively. A propensity-matched score analysis showed a higher clinical response rate at week 14 in the SCi group and higher treatment persistence in the IVi group. Regarding long-term outcomes, dose escalation and discontinuation due to the primary failure of the first anti-TNF and more severe disease activity at the beginning of the second anti-TNF were inversely associated with clinical remission | ||
| 520 | |a Conclusion: The use of a second anti-TNF for UC seems to be reasonable in terms of efficacy, although it is particularly reduced in the case of the primary failure of the first anti-TNF. Whether the second anti-TNF is infliximab or subcutaneous does not seem to affect efficacy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adalimumab | |
| 650 | 4 | |a anti-TNF | |
| 650 | 4 | |a golimumab | |
| 650 | 4 | |a infliximab | |
| 650 | 4 | |a switch | |
| 650 | 4 | |a ulcerative colitis | |
| 700 | 1 | |a Torres, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Tosca-Cuquerella, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Aldehuelo, Rubén |e verfasserin |4 aut | |
| 700 | 1 | |a Rivero, Montserrat |e verfasserin |4 aut | |
| 700 | 1 | |a Iborra, Marisa |e verfasserin |4 aut | |
| 700 | 1 | |a González-Vivo, María |e verfasserin |4 aut | |
| 700 | 1 | |a Vera, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a de Castro, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Bujanda, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Barreiro-de Acosta, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a González-Muñoza, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Calvet, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Benítez, José Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Llorente-Barrio, Mónica |e verfasserin |4 aut | |
| 700 | 1 | |a Surís, Gerard |e verfasserin |4 aut | |
| 700 | 1 | |a Cañete, Fiorella |e verfasserin |4 aut | |
| 700 | 1 | |a Arias-García, Lara |e verfasserin |4 aut | |
| 700 | 1 | |a Monfort, David |e verfasserin |4 aut | |
| 700 | 1 | |a Castaño-García, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Alonso, Francisco Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Huguet, José M |e verfasserin |4 aut | |
| 700 | 1 | |a Marín-Jímenez, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Lorente, Rufo |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Cardona, Albert |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrer, Juan Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Camo, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Gisbert, Javier P |e verfasserin |4 aut | |
| 700 | 1 | |a Pajares, Ramón |e verfasserin |4 aut | |
| 700 | 1 | |a Gomollón, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Castro-Poceiro, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Morales-Alvarado, Jair |e verfasserin |4 aut | |
| 700 | 1 | |a Llaó, Jordina |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Galindo, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro, Mercè |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez-García, Nuria |e verfasserin |4 aut | |
| 700 | 1 | |a Carrillo-Palau, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Blázquez-Gómez, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Sesé, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Almela, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Ramírez de la Piscina, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Taxonera, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Lago, Iago |e verfasserin |4 aut | |
| 700 | 1 | |a Cabrinety, Lidia |e verfasserin |4 aut | |
| 700 | 1 | |a Vela, Milagros |e verfasserin |4 aut | |
| 700 | 1 | |a Mínguez, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Mesonero, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a García, María José |e verfasserin |4 aut | |
| 700 | 1 | |a Aguas, Mariam |e verfasserin |4 aut | |
| 700 | 1 | |a Márquez, Lucía |e verfasserin |4 aut | |
| 700 | 1 | |a Silva Porto, Marisol |e verfasserin |4 aut | |
| 700 | 1 | |a Pineda, Juan R |e verfasserin |4 aut | |
| 700 | 1 | |a García-Etxebarría, Koldo |e verfasserin |4 aut | |
| 700 | 1 | |a Bertoletti, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Brunet, Eduard |e verfasserin |4 aut | |
| 700 | 1 | |a Mañosa, Míriam |e verfasserin |4 aut | |
| 700 | 1 | |a Domènech, Eugeni |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic advances in gastroenterology |d 2008 |g 17(2024) vom: 16., Seite 17562848231221713 |w (DE-627)NLM193041979 |x 1756-283X |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2024 |g day:16 |g pages:17562848231221713 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/17562848231221713 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2024 |b 16 |h 17562848231221713 | ||